Kenvue (NYSE:KVUE) Price Target Raised to $29.00

Kenvue (NYSE:KVUE) had its price target boosted by Canaccord Genuity Group from $24.00 to $29.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently weighed in on the stock. Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Citigroup reduced their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $23.75.

Kenvue Trading Up 1.2 %

NYSE KVUE opened at $23.46 on Wednesday. The company has a market capitalization of $44.83 billion, a PE ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.45. The company has a fifty day moving average of $21.64 and a 200 day moving average of $22.32. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts forecast that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.50%. Kenvue’s dividend payout ratio is presently 154.72%.

Institutional Trading of Kenvue

Large investors have recently bought and sold shares of the business. National Pension Service grew its stake in shares of Kenvue by 14.5% in the 3rd quarter. National Pension Service now owns 2,829,772 shares of the company’s stock valued at $65,453,000 after buying an additional 357,672 shares during the period. HF Advisory Group LLC grew its stake in shares of Kenvue by 15.4% in the 3rd quarter. HF Advisory Group LLC now owns 110,205 shares of the company’s stock valued at $2,549,000 after buying an additional 14,686 shares during the period. Concurrent Investment Advisors LLC grew its stake in shares of Kenvue by 131.9% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company’s stock valued at $1,238,000 after buying an additional 30,438 shares during the period. M&G PLC grew its stake in shares of Kenvue by 538.0% in the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after buying an additional 3,660,730 shares during the period. Finally, Blake Schutter Theil Wealth Advisors LLC purchased a new stake in shares of Kenvue in the 3rd quarter valued at approximately $370,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.